Immunization and Vaccination Payment and Claims Guidelines
This document governs payment, claims filing, and coverage guidance for immunizations and vaccinations for Blue Cross & Blue Shield of Rhode Island members, including Medicare (BlueCHiP for Medicare) and Commercial products; it addresses state-supplied vaccines, retail pharmacy program participation, and coding/administrative requirements.
No material clinical or coverage changes in this revision.
Coverage Criteria
inv-01: Coverage criteria
Coverage varies by product and vaccine. Specific Medicare Part B vaccines and CDC/FDA-recommended vaccines are covered as described below; refer to member benefit documents for group-specific variations.
ALL of the following
ANY of the following
- Pneumococcal pneumonia (Part B)
- Influenza virus (Part B)
- Hepatitis B for individuals at high or intermediate risk (requires ICD-10 diagnosis code Z23)
- Tetanus and other vaccines directly related to treatment of an injury or direct exposure to disease/condition (e.g., rabies — requires ICD-10 diagnosis code Z20.3).
- Documentation requirement for injury/exposure-related vaccines
Claims for tetanus vaccine coverage under Part B must be filed with a diagnosis indicating the vaccine was needed due to an injury.
ALL of the following
- Vaccinations/immunizations are covered when recommended by CDC and AAP and when FDA guidelines are met.
- Group/contract benefit variation
Benefits may vary by group/contract; refer to the Evidence of Coverage/Benefit Booklet for applicable benefits.
ALL of the following
- State of Rhode Island Department of Health provides biologicals for pediatric immunizations; BCBSRI does not reimburse providers for DOH-supplied vaccines; BCBSRI follows DOH guidance for state-supplied vaccine lists and shortages.
ALL of the following
- Providers must submit both the administration procedure code and the vaccine/toxoid procedure code when the provider purchases the vaccine.
- Submit modifier 22 to identify vaccines supplied by the physician (non-state-supplied) to facilitate pricing that includes allowance for the vaccine.
ALL of the following
- E/M services should not be filed with immunization unless separately identifiable; use modifier 25 to report a separately identifiable E/M.
ALL of the following
- BlueCHiP for Medicare plans do not cover travel-related vaccines; travel clinic counseling is typically noncovered for Commercial products (codes 99401-99404, 99411-99412) — members may be billed and must be notified.
ALL of the following
- Part D generally covers vaccines not reimbursed under Medicare Parts A or B; providers may contact the Part D plan to inquire about coverage and supply supporting information to facilitate beneficiary vaccine coverage.
inv-02: Coverage criteria by product
Coverage is defined by explicit lists of CPT/HCPCS codes and by product (BlueCHiP for Medicare vs Commercial). Some codes are excluded or pending FDA approval.
ALL of the following
- Listed CPT/HCPCS codes include (examples shown in policy): 90630, 90653-90676, 90682-90689, 90694, 90714-90756, Q2034-Q2038.
- Diagnosis code requirements for specific Part B vaccines
When billing Rabies or Hepatitis B for individuals at risk, include ICD-10 diagnosis codes Z20.3 (rabies exposure) or Z23 (encounter for immunization) as applicable.
ALL of the following
- Travel vaccine and counseling distinctions
Some travel counseling codes are non-covered when used for travel (see exclusions).
ALL of the following
Coding and Billing
| 90630 | Influenza virus vaccine; quadrivalent (IIV4), split virus, preservative free, for intradermal use |
| 90653 | Influenza virus vaccine, inactivated, subunit, adjuvanted, for intramuscular use |
| 90654 | Influenza virus vaccine, trivalent (IIV3) split virus, preservative-free, for intradermal use |
| 90655 | Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.25 mL dosage, for intramuscular use |
| 90656 | Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use |
| 90657 | Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use |
| 90658 | Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use |
| 90660 | Influenza virus vaccine, trivalent; live (LAIV3), for intranasal use |
| 90661 | Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use |
| 90662 | Influenza virus vaccine (IIV), split, preservative enhanced immunogenicity via increased antigen content; for intramuscular use |
| 90476 | Adenovirus vaccine, type 4, live, for oral use |
| 90477 | Adenovirus vaccine, type 7, live, for oral use |
| 90581 | Anthrax vaccine, for subcutaneous use |
| 90587 | Dengue vaccine, quadrivalent; live, 3 dose schedule, for subcutaneous use |
| 90619 | Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent; tetanus toxoid carrier (MenACWY-TT), for intramuscular use |
| 90620 | Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C), 2 dose schedule, for intramuscular use |
| 90621 | Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), 2 or 3 dose schedule; for intramuscular use |
| 90630 | Influenza virus vaccine; quadrivalent (IIV4), split virus, preservative free, for intradermal use |
| 90632 | Hepatitis A vaccine (HepA), adult dosage, for intramuscular use |
| 90633 | Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use |
| 90666 | Influenza virus vaccine (IIV), pandemic formulation, split virus, preservative free (pending FDA approval) |
| 90667 | Influenza virus vaccine (IIV), pandemic formulation, split virus, adjuvanted (pending FDA approval) |
| 90668 | Influenza virus vaccine (IIV), pandemic formulation, split virus (pending FDA approval) |
Provider Actions and Requirements
Prior authorization not applicable
Prior authorization is not required for immunizations or vaccine administration under this policy.
Part D coverage inquiry for non‑formulary vaccines
If a vaccine is not listed on a Part D plan formulary, providers may contact the Part D plan to inquire about coverage and provide any supporting information needed to facilitate beneficiary vaccine coverage.
- Contact the member's Part D plan when the vaccine is not on the plan formulary.
- Supply supporting documentation as requested to help establish medical necessity and enable reimbursement under Part D.
Definitions and Required Codes
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.